Strongbridge Biopharma — Investor Presentation (November 2019)
29 slides from Strongbridge Biopharma's investor presentation, Nov 19, 2019
Slide 1: Strongbridge Biopharma plc November 2019
Strongbridge Biopharma plc November 2019
Slide 2: Forward-looking statements
Forward-looking statements This document contains forward‐looking statements relating to the Company’s strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statement
Slide 3: Pipeline
Pipeline Indication/ Target Disease Pre- clinical Phase 1 Phase 2 Phase 3 Marketed Commercial Rights Rare Endocrinology RECORLEV™ (levoketoconazole) Endogenous Cushing’s syndrome (CS) Global veldoreotide modified-release Conditions modifiable through activation of somatostatin receptors, such as Cus
Slide 4: Recorlev (levoketoconazole)
Recorlev (levoketoconazole)
Slide 5: Endogenous Cushing's syndrome overview
Endogenous Cushing’s syndrome overview Endogenous Cushing’s syndrome ACTH- dependent (80-85%) Primary adenoma (Cushing’s disease) (75-80%) Ectopic ACTH or CRH tumors (15-20%) ACTH-independent (15-20%) Pituitary & adrenal carcinomas (~90%) Hyperplasia (rare) 5 Underlying cause is chronic exposure to
Slide 6: Treatment paradigm & prevalence
Treatment paradigm & prevalence 6 Adult Endogenous Diagnosed (excluding adrenal carcinoma / malignant causes) ~20,500 Endogenous Cushing’s Syndrome U.S. diagnosed prevalence ~25,000 Rx Treated ~8,000 pats. Not-controlled ~3,200 pats. Controlled ~4,800 pats. Source: Company-sponsored research
Slide 7: Levoketoconazole is the sole active enantiomer of ketoconazole in Cushing's syndrome
Levoketoconazole is the sole active enantiomer of ketoconazole in Cushing’s syndrome 7 KETOCONAZOLE Racemate with Two Enantiomers DEXTROKETOCONAZOLE • Right-handed enantiomer • Estimated to contribute essentially no activity towards the inhibition of adrenal cortisol synthesis by ketoconazole Auchus
Slide 8: SONICS Phase 3 study design
EXTENDED EVALUATION: 6 months MAINTENANCE: 6 months Maintain mUFC normalization with fixed therapeutic dose DOSE TITRATION: 2 to 21 weeks Titrate in 150 mg increments up to max 600 mg 2x daily until mUFC normalization achieved or therapeutic dose is otherwise established SONICS: A Phase 3, multi-cen
Slide 9: SONICS achieved statistical significance for primary endpoint at end of maintenance
SONICS achieved statistical significance for primary endpoint at end of maintenance ◼ Primary endpoint achieved statistical significance with 30% of patients (29/94) achieving mUFC normalization without dose increase (95% CI: 21%, 40%; p=.0154 vs null hypothesis), ITT analysis* 9 ◼ Expanded mUFC “re
Slide 10: SONICS achieved statistical significance in key secondary endpoints and QoL
SONICS achieved statistical significance in key secondary endpoints and QoL at end of maintenance phase ◼ Five key cardiovascular (CV) secondary endpoints with favorable changes from baseline – Improvements in HbA1c and fasting blood glucose were more pronounced among patients with diabetes mellitus
Slide 11: Adverse events in SONICS
Adverse events in SONICS Combined dose titration and maintenance phases, ITT ◼ In general, there were no unforeseen or unexpected safety issues in the study ◼ No late onset of adverse events of special interest; all occurred in the maintenance phase of the study 11 *Includes all alanine aminotransfe
Slide 12: Liver safety findings in context
Liver safety findings in context (full study, 12 months) ◼ 3.2% of patients had an ALT elevation >5x ULN ◼ 10.6% of patients had an ALT elevation >3x ULN (includes those greater than 5x ULN) – All occurred on or before day-60 visit of maintenance – All were reversible upon discontinuation without cl
Slide 13: LOGICS Phase 3 trial design
LOGICS Phase 3 trial 13 LEVOKETOCONAZOLE- NAÏVE-ONLY DOSE TITRATION: RANDOMIZED WITHDRAWAL: (Active) RANDOMIZED WITHDRAWAL: (Placebo) RESTORATION PHASE Enrollment Range of ~ 2 to 9.5 weeks Primary endpoint: Loss of Response Design: Double-blind, placebo-controlled, randomized-withdrawal study intend
Slide 14: LOGICS Phase 3 trial enrollment & projection
LOGICS Phase 3 trial enrollment & projection ◼ Enrollment (as of November 5, 2019) – Approximately two-thirds enrolled towards target of 46-54 – Projections indicate all patients required to complete enrollment have been identified, with most in titration-maintenance and the remainder in screening ◼
Slide 15: Cushing's syndrome represents a commercial opportunity where patients need new treatment options
Cushing’s syndrome represents a commercial opportunity where patients are in need of new treatment options Source: Company-sponsored research Market Potential Unmet Need Recorlev Profile Pricing and Reimbursement ▪ Estimated diagnosed and pharmacologic treated population ▪ ~25,000 CS diagnosed patie
Slide 16: Unmet needs center around efficacy and safety
Unmet needs center around efficacy and safety 16 Source: Company-sponsored research Unmet Need Safer Treatment Options Improved Efficacy CS Patients More Novel Options High High High Initial Market Assessment Findings There is a desire for products with better efficacy, predictable treatment respons
Slide 17: Recorlev anticipated to be differentiated from ketoconazole
Recorlev anticipated to be differentiated from ketoconazole 17 Recorlev ketoconazole Indication Anticipated labeling for the treatment of CS Indicated as a last line anti-fungal; FDA admonition of use in CS Clinical data Well characterized in two Phase 3 clinical trials Not well-studied prospectivel
Slide 18: Pricing and reimbursement
Pricing and reimbursement ◼ Pricing – Rare disease pricing corridor exists for CS – Current CS branded therapies are priced from $165k to $335k annually • Can reach up to $669k for higher dosing levels – Branded agents have fairly broad payer coverage ◼ Reimbursement – Largest insurance group for CS
Slide 19: Existing commercial infrastructure
Existing commercial infrastructure 19 Company‘s existing commercial infrastructure may accelerate Recorlev’s time to peak penetration Fully operational patient services, including specialty pharmacy and patient access managers; significant reimbursement experience Established relationships with Cush
Slide 20: Keveyis (dichlorphenamide)
Keveyis (dichlorphenamide) The first and only FDA-approved therapy for primary periodic paralysis* * FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis
Slide 21: Primary periodic paralysis: a spectrum of rare, chronic, genetic, neuromuscular disorders
Primary periodic paralysis: a spectrum of rare, chronic, genetic, neuromuscular disorders 21 Causes recurrent, progressive, and debilitating episodes of muscle weakness and temporary paralysis2-4 Symptoms: clumsiness, extreme fatigue, weakness, palpitations, pain Triggers: may include potassium, car
Slide 22: Keveyis approved for the treatment of PPP in the US
* Based on Strongbridge analysis of medical claims database. Identified patients were required to have medical activity of any type in the last 12-36 months. ~4,000 – 5,000* Keveyis approved for the treatment of PPP in the US ◼ The first and only FDA-approved therapy indicated for the treatment of p
Slide 23: Treatment with Keveyis decreased weekly attack rates
Treatment with Keveyis decreased weekly attack rates 23 Study 2 Hyperkalemic Study 1: Sansone VA, et al. Neurology 2016;86:1408-1416 Study 2: Tawil R, et al. Ann Nuerol. 2000; 47:46-53. 4.0 2.0 1.8 1.1 4.8 0.9 2.4 0.3 Hyperkalemic Hypokalemic Baseline Post- Treatment Baseline Post- Treatment Baselin
Slide 24: Our commitment to primary periodic paralysis
Our commitment to primary periodic paralysis 24 Personalized Support Access Assistance Community Connection Genetic Testing Education & Public Awareness Suite of patient services
Slide 25: Strategic priorities & revenue guidance
Strategic priorities & revenue guidance 25 Achieved positive contribution margin; continue to drive revenue growth with focused financial resources to increase product profitability Pursue life cycle opportunities to extend exclusivity runway beyond 2022; update to be provided in 1H 2020 First three
Slide 26: IP & Financials
IP & Financials
Slide 27: Intellectual property and orphan exclusivity
Intellectual property and orphan exclusivity IP Orphan exclusivity US EU US EU Recorlev Veldoreotide Filed patent application for novel formulation Keveyis Exploring options US rights only US rights only 10 years 27 7 years 2030 2026 Method of use: reducing CRP levels and systemic inflammation Metho
Slide 28: Financial highlights (as of 9/30/2019)
Financial highlights (as of 9/30/2019) ◼ ~$79.6 million in cash; no debt ◼ ~54.2 million shares outstanding ◼ Cash runway through 2Q 2021 ◼ $6M payment anticipated in 4Q 2019 in connection with the termination of Strongbridge’s agreement with Novo Nordisk for the promotion of Macrilen™ in the U.S. ◼
Slide 29: Strongbridge Biopharma plc November 2019
Strongbridge Biopharma plc November 2019
Strongbridge Biopharma — Investor Presentation (November 2019) on 6ix